{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014777","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.499380+00:00","generated_at":"2026-06-24T04:31:02.418747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences reports Q2 net loss of $15.1M; FDA clears IND for TYRA-300","bullets":["Q2 2022 net loss $15.1M vs $5.5M in Q2 2021; R&D expense $12.0M vs $4.4M.","Cash and cash equivalents $275.1M as of June 30, 2022, sufficient to fund operations.","FDA cleared IND for TYRA-300 (FGFR3 inhibitor) to begin Phase 1/2 SURF301 study in metastatic urothelial carcinoma.","IND for TYRA-200 (FGFR2 inhibitor) on track for submission in 2H 2022 with initial focus on intrahepatic cholangiocarcinoma.","Key leadership hires: Sarah Honig (VP Corp Dev) and Ali Fawaz (General Counsel/Secretary)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014777","json":"https://secwatch.observer/filing/0000950170-22-014777.json","markdown":"https://secwatch.observer/filing/0000950170-22-014777.md","text":"https://secwatch.observer/filing/0000950170-22-014777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022014777/0000950170-22-014777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017022014777/tyra-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:31:02.418747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}